{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:36:29Z","timestamp":1790800589430,"version":"4.1.0"},"reference-count":50,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"13","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["Circulation"],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:sec>\n                    <jats:title>BACKGROUND:<\/jats:title>\n                    <jats:p>Giant cell arteritis is associated with increased cardiovascular risk, potentially related to systemic inflammation, vascular injury, and glucocorticoid exposure. Whether steroid-sparing therapies differentially influence cardiovascular outcomes in giant cell arteritis remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>METHODS:<\/jats:title>\n                    <jats:p>We conducted a nationwide observational cohort study emulating a target trial using the French National Health Data System from January 1, 2012, to December 31, 2024. We included patients hospitalized for incident giant cell arteritis who initiated tocilizumab or methotrexate within 6 months after discharge. The primary outcome was the first major adverse cardiovascular event, defined as any coronary event, ischemic stroke, or all-cause death. Treatment effects were estimated with a clone-censor-weight approach with inverse probability of censoring weighting. We estimated 2-year cumulative incidences, absolute risk differences, and hazard ratios with 95% CIs.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>RESULTS:<\/jats:title>\n                    <jats:p>In 1997 patients with incident giant cell arteritis (mean age, 73.1\u00b18.3 years; 70.4% women), 1095 initiated tocilizumab and 902 initiated methotrexate within 6 months after discharge. At 2 years, the cumulative incidence of major adverse cardiovascular events was 6.4% (95% CI, 4.9%\u20137.9%) with tocilizumab and 10.7% (95% CI, 8.4%\u201312.9%) with methotrexate (risk difference, \u22124.3% [95% CI, \u22126.6% to \u22121.7%]). Tocilizumab initiation was associated with a lower risk of major adverse cardiovascular events (hazard ratio, 0.60 [95% CI, 0.48\u20130.75]), driven by fewer coronary events (hazard ratio, 0.55 [95% CI, 0.37\u20130.84]) and all-cause deaths (hazard ratio, 0.53 [95% CI, 0.36\u20130.74]). Results were consistent in sensitivity analyses using alternative grace periods, corticosteroid dose thresholds, restriction to the 2017 to 2024 period, and a per-protocol\u2013analogous approach. Negative control outcomes did not differ meaningfully between treatment strategies.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>CONCLUSIONS:<\/jats:title>\n                    <jats:p>In this nationwide target trial emulation of incident giant cell arteritis, initiation of tocilizumab was associated with a lower risk of major adverse cardiovascular events compared with methotrexate, primarily through a reduction in coronary events and all-cause deaths.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>REGISTRATION:<\/jats:title>\n                    <jats:p>\n                      URL:\n                      <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/www.clinicaltrials.gov\">https:\/\/www.clinicaltrials.gov<\/jats:ext-link>\n                      ; Unique identifier: NCT07459335.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/circulationaha.126.080365","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T12:15:14Z","timestamp":1788005714000},"page":"1187-1199","update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Tocilizumab Is Associated With a Lower Incidence of Major Adverse Cardiovascular Events in Giant Cell Arteritis"],"prefix":"10.1161","volume":"154","clinical-trial-number":[{"clinical-trial-number":"nct07459335","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4571-6219","authenticated-orcid":true,"given":"Alexis F.","family":"Guedon","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France (A.F.G., F.C.)."},{"name":"Sorbonne Universit\u00e9, Service de M\u00e9decine Interne, AP-HP, H\u00f4pital Saint Antoine, Paris, France (A.F.G., E.G., O.F., A. Mekinian)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6727-4992","authenticated-orcid":true,"given":"Patrice","family":"Cacoub","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Paris, France (P.C., A. Mirouse, D.S.)."},{"name":"Centre National de R\u00e9f\u00e9rence Maladies Autoimmunes Syst\u00e9miques Rares, Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA); Inflammation-Immunopathology-Biotherapy Department (DMU 3iD); CIC Biotherapy; INSERM 959, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, AP-HP, Paris, France (P.C., A. Mirouse, D.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8672-7918","authenticated-orcid":true,"given":"Fabrice","family":"Carrat","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Institut National de la Sant\u00e9 et de la Recherche M\u00e9dicale, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique, Paris, France (A.F.G., F.C.)."},{"name":"Groupe Hospitalier Sorbonne Universit\u00e9, D\u00e9partement de Sant\u00e9 Publique, H\u00f4pital Saint-Antoine, APHP, Paris, France (F.C.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0821-9990","authenticated-orcid":true,"given":"Olivier","family":"Espitia","sequence":"additional","affiliation":[{"name":"Department of Internal and Vascular Medicine, Nantes Universit\u00e9, CHU Nantes, l\u2019Institut du Thorax, INSERM UMR1087\/CNRS UMR 6291, Team III Vascular &amp; Pulmonary Diseases, Nantes, France (O.E.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5755-8043","authenticated-orcid":true,"given":"Adrien","family":"Mirouse","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Paris, France (P.C., A. Mirouse, D.S.)."},{"name":"Centre National de R\u00e9f\u00e9rence Maladies Autoimmunes Syst\u00e9miques Rares, Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA); Inflammation-Immunopathology-Biotherapy Department (DMU 3iD); CIC Biotherapy; INSERM 959, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, AP-HP, Paris, France (P.C., A. Mirouse, D.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0149-8440","authenticated-orcid":true,"given":"Etienne","family":"Ghrenassia","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Service de M\u00e9decine Interne, AP-HP, H\u00f4pital Saint Antoine, Paris, France (A.F.G., E.G., O.F., A. Mekinian)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Fain","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Service de M\u00e9decine Interne, AP-HP, H\u00f4pital Saint Antoine, Paris, France (A.F.G., E.G., O.F., A. Mekinian)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ars\u00e8ne","family":"Mekinian","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, Service de M\u00e9decine Interne, AP-HP, H\u00f4pital Saint Antoine, Paris, France (A.F.G., E.G., O.F., A. Mekinian)."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3628-9996","authenticated-orcid":true,"given":"David","family":"Saadoun","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9s AP-HP, Groupe Hospitalier Piti\u00e9-Salp\u00eatri\u00e8re, D\u00e9partement de M\u00e9decine Interne et Immunologie Clinique, Paris, France (P.C., A. Mirouse, D.S.)."},{"name":"Centre National de R\u00e9f\u00e9rence Maladies Autoimmunes Syst\u00e9miques Rares, Centre National de R\u00e9f\u00e9rence Maladies Autoinflammatoires et Amylose Inflammatoire (CEREMAIA); Inflammation-Immunopathology-Biotherapy Department (DMU 3iD); CIC Biotherapy; INSERM 959, Groupe Hospitalier Pitie\u0301-Salpe\u0302trie\u0300re, AP-HP, Paris, France (P.C., A. Mirouse, D.S.)."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"publisher","DOI":"10.7326\/M12-3046"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kev262"},{"key":"e_1_3_3_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2019.01.009"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurjpc\/zwag034"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2016.05.009"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kew482"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.md.0000145369.25558.b5"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1186\/1710-1492-9-30"},{"key":"e_1_3_3_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.21568"},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2019-215672"},{"key":"e_1_3_3_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)00560-2"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1613849"},{"key":"e_1_3_3_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/art.10262"},{"key":"e_1_3_3_15_2","first-page":"495","article-title":"A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA).","volume":"19","author":"Spiera RF","year":"2001","unstructured":"Spiera RF, Mitnick HJ, Kupersmith M, Richmond M, Spiera H, Peterson MG, Paget SA. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol. 2001;19:495\u2013501.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-134-2-200101160-00010"},{"key":"e_1_3_3_17_2","unstructured":"Samson M Bourredjem A Outh R Grobost V Lifermann F Direz G Ribeiro E Oziol E Devauchelle V Ebbo M et al. MEthotrexate versus TOcilizumab for treatment of Giant cell Arteritis (METOGiA trial): a multicenter randomized controlled trial. ACR Meeting Abstracts. Accessed January 22 2026. https:\/\/acrabstracts.org\/abstract\/methotrexate-versus-tocilizumab-for-treatment-of-giant-cell-arteritis-metogia-trial-a-multicenter-randomized-controlled-trial\/"},{"key":"e_1_3_3_18_2","volume-title":"MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial","author":"ClinicalTrials.gov","year":"2025","unstructured":"ClinicalTrials.gov. MEthotrexate Versus TOcilizumab for Treatment of GIant Cell Arteritis: a Multicenter, Randomized, Controlled Trial. 2025. Accessed January 22, 2026. https:\/\/clinicaltrials.gov\/study\/NCT03892785"},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2413449"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109927"},{"key":"e_1_3_3_21_2","volume-title":"FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions","author":"U.S. Food and Drug Administration","year":"2025","unstructured":"U.S. Food and Drug Administration. FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions. 2025. Accessed January 19, 2026. https:\/\/fda.gov\/drugs\/drug-safety-and-availability\/fda-requires-warnings-about-increased-risk-serious-heart-related-events-cancer-blood-clots-and-death"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.respe.2017.05.004"},{"key":"e_1_3_3_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(15)00027-7"},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i2002"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2015.6205"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00198-1"},{"key":"e_1_3_3_27_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1707914"},{"key":"e_1_3_3_28_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2021372"},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912388"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809798"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1152\/ajpcell.00235.2017"},{"key":"e_1_3_3_32_2","doi-asserted-by":"publisher","DOI":"10.1161\/ATVBAHA.111.229435"},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000148135.08582.97"},{"key":"e_1_3_3_34_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.cir.101.15.1767"},{"key":"e_1_3_3_35_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000158479.58589.0A"},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(11)61931-4"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(12)60110-X"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41525-019-0097-4"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy310"},{"key":"e_1_3_3_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keh058"},{"key":"e_1_3_3_41_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-020-05005-7"},{"key":"e_1_3_3_42_2","doi-asserted-by":"publisher","DOI":"10.1002\/1529-0131(199808)41:8<1497::AID-ART22>3.0.CO;2-Z"},{"key":"e_1_3_3_43_2","first-page":"S13","article-title":"Predictors of cerebrovascular accidents in giant cell arteritis in a defined population.","volume":"22","author":"Pego-Reigosa R","year":"2004","unstructured":"Pego-Reigosa R, Garcia-Porrua C, Pi\u00f1eiro A, Dierssen T, Llorca J, Gonzalez-Gay MA. Predictors of cerebrovascular accidents in giant cell arteritis in a defined population. Clin Exp Rheumatol. 2004;22(suppl 36):S13\u2013S17.","journal-title":"Clin Exp Rheumatol"},{"key":"e_1_3_3_44_2","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.161033"},{"key":"e_1_3_3_45_2","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11041005"},{"key":"e_1_3_3_46_2","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209775"},{"key":"e_1_3_3_47_2","doi-asserted-by":"publisher","DOI":"10.1136\/ard-2022-222259"},{"key":"e_1_3_3_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)01349-6"},{"key":"e_1_3_3_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.therap.2024.05.003"},{"key":"e_1_3_3_50_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.21383"},{"key":"e_1_3_3_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2665-9913(21)00038-2"}],"container-title":["Circulation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/CIRCULATIONAHA.126.080365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T19:37:01Z","timestamp":1790797021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/CIRCULATIONAHA.126.080365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":50,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2026,9,29]]}},"alternative-id":["10.1161\/CIRCULATIONAHA.126.080365"],"URL":"https:\/\/doi.org\/10.1161\/circulationaha.126.080365","relation":{},"ISSN":["0009-7322","1524-4539"],"issn-type":[{"value":"0009-7322","type":"print"},{"value":"1524-4539","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"2026-03-07","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-29","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-29","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}